期刊文献+
共找到5篇文章
< 1 >
每页显示 20 50 100
家兔持续静脉输注HX0507的药代动力学研究
1
作者 李蕊 李杰 +4 位作者 张文胜 李莉娥 符义刚 蒋学华 刘进 《四川大学学报(医学版)》 CAS CSCD 北大核心 2009年第2期337-340,共4页
目的观察家兔持续恒速静脉输注水溶性丙泊酚(HX0507)后,HX0507与其活性代谢产物PROPOFOLHX0507的药代动力学特征。方法30只成年家兔雌雄各半,随机分为高、中、低3个速率组,分别以3.0mg/(kg.min)2、.5 mg/(kg.min)2、.0 mg/(kg.min)的速... 目的观察家兔持续恒速静脉输注水溶性丙泊酚(HX0507)后,HX0507与其活性代谢产物PROPOFOLHX0507的药代动力学特征。方法30只成年家兔雌雄各半,随机分为高、中、低3个速率组,分别以3.0mg/(kg.min)2、.5 mg/(kg.min)2、.0 mg/(kg.min)的速率持续恒速静脉输注HX0507 60 min。各组家兔分别于给药前后采集动、静脉血样,应用高效液相色谱-质谱检测法检测血浆中HX0507、PROPOFOLHX0507、甲酸盐的药物浓度,应用DAS ver1.0软件计算药代动力学参数。家兔的生命体征及生理反射作为其药效学的评价指标。结果高、中、低3个速率组HX0507的主要药代参数:t1/2α分别为(4.0±1.2)min、(4.1±0.9)min、(4.2±0.7)min;AUC∞分别为〔(967.4±659.6)×104〕mg/(L.min)、〔(935.0±539.1)×104〕mg/(L.min)、〔(809.2±551.4)×104〕mg/(L.min);Tmax分别为(38.2±18.2)min(、43.8±16.4)min(、28.2±14.6)min;Cmax分别为(238.3±190.7)mg/mL、(219.9±133.0)mg/mL(、179.4±113.2)mg/mL;高、中、低3个速率组PROPOFOLHX0507的主要药代参数:t1/2α分别为(7.5±3.8)min(、9.7±2.7)min、(9.7±2.9)min;AUC∞分别为(736.6±841.6)mg/(L.min)、(731.4±302.2)mg/(L.min)(、682.3±271.5)mg/(L.min);Tmax分别为(45.5±9.3)min、(53.0±11.6)min(、54.0±7.8)min;Cmax分别为〔(12.2±9.0)×10-3〕mg/mL、〔(12.7±6.0)×10-3〕mg/mL、〔(10.3±3.7)×10-3〕mg/mL。结论HX0507、PROPOFOLHX0507均符合一级消除动力学的二室模型。 展开更多
关键词 hx0507 持续恒速输注 药代动力学 家兔
下载PDF
Effect of HX0507,a water-soluble propofol pro-drug,on subarachnoid hemorrhage-induced cerebral vasospasm in rabbits
2
作者 Xinsheng Xue Tao Zhu +2 位作者 Wensheng Zhang Yan Kang Jin Liu 《Neural Regeneration Research》 SCIE CAS CSCD 2009年第11期890-895,共6页
BACKGROUND: Propofol has been shown to attenuate neuronal injury in a number of experimental conditions. However, its effect in models of cerebral ischemia after subarachnoid hemorrhage (SAH) remains controversial.... BACKGROUND: Propofol has been shown to attenuate neuronal injury in a number of experimental conditions. However, its effect in models of cerebral ischemia after subarachnoid hemorrhage (SAH) remains controversial. OBJECTIVE: To explore the effects of intracisternal injection of HX0507, a water-soluble propofol prodrug, on basilar artery vasospasm and brain tissue injury in a rabbit model of SAH. DESIGN, TIME AND SETTING: A randomized, controlled, in vivo animal experiment based on behavior and morphology. The study was performed at the Laboratory of Anesthesiology and Critical Care Medicine, West China Hospital, Sichuan University from April to December 2007. MATERIALS: HX0507 was provided by the Laboratory of Anesthesiology and Critical Care Medicine, West China Hospital of Sichuan University. METHODS: A total of 30 healthy, male, New Zealand rabbits were randomly assigned to sham-operation, SAH-control, and SAH-HX0507 groups, with 10 animals in each group. The single-hemorrhage SAH model was established by injecting autologous arterial blood (1.0 mL/kg) into the cisterna magna in the SAH-control and SAH-HX0507 groups, while the sham-operation group was injected with normal saline (1.0 mL/kg). Thirty minutes after injection, the sham-operation and SAH-control groups were injected with normal saline (0.1 mL/kg) into the cisterna magna, while the SAH-HX0507 group received an injection of HX0507 (4.8 mg/kg). MAIN OUTCOME MEASURES: The cross-sectional area and corrugation coefficients of basilar arteries and hippocampal CA1 neuronal densities were measured 48 hours after SAH (peak stage of vasospasm) using the Computer-Assisted Stereological Toolbox system. The ultrastructural structure of the basilar artery wall was examined by transmission electron microscopy. In addition, neurological behavioral impairment was evaluated by appetite score at pre-SAH, and 1 and 2 days after SAH. RESULTS: The cross-sectional area of basilar arteries and hippocampal CA1 neuronal densities, as well as ultrastructural structure scores of the SAH-control group were significantly less than the other groups (P 〈 0.01 or P 〈 0.05), while the corrugation coefficients of basilar arteries and appetite score 2 days after SAH were significantly greater than the other groups (P 〈 0.01 or P 〈 0.05). The appetite score 1 day after modeling was remarkably greater than the SAH-control group (P 〈 0.05). However, no significant difference was determined between the sham-operation and SAH-HX0507 groups (P 〉 0.05). CONCLUSION: Intracisternal administration of HX0507 attenuated basilar artery vasospasm and hippocampal ischemic injury in a rabbit model of SAH. 展开更多
关键词 hx0507 subarachnoid hemorrhage basilar artery vasospasm
下载PDF
静脉全麻药HX0507体内活性代谢物丙泊酚的药动学研究 被引量:1
3
作者 姚力尹 李蕊 +4 位作者 伊晓倩 徐小平 钱广生 康仪 张文胜 《华西药学杂志》 CAS CSCD 北大核心 2012年第3期298-301,共4页
目的研究单次iv给予HX0507后,在健康受试者体内活性代谢物丙泊酚的药动学特征。方法 30名健康受试者分组(10、20、30 mg·kg-1),分别接受单次iv HX0507,以GC-MS法测定丙泊酚的血药浓度,用DAS 2.0药动学软件以非房室模型计算其药动... 目的研究单次iv给予HX0507后,在健康受试者体内活性代谢物丙泊酚的药动学特征。方法 30名健康受试者分组(10、20、30 mg·kg-1),分别接受单次iv HX0507,以GC-MS法测定丙泊酚的血药浓度,用DAS 2.0药动学软件以非房室模型计算其药动学参数。结果受试者单次iv低、中、高浓度HX0507后的主要药动学参数为:t1/2分别为150.72±42.63、133.35±33.76、145.77±51.76 min、Cmax分别为1.96±0.47、4.27±1.54、9.71±4.78 mg·L-1,AUC0-t分别为174.80±33.49、397.34±62.19、642.28±90.69 mg·min·L-1。结论 HX0507的活性代谢物丙泊酚在10~30 mg·kg-1给药剂量范围内,Cmax和AUC与给药剂量呈线性相关,在体内呈现线性药动学特性。 展开更多
关键词 hx0507 丙泊酚 药动学
原文传递
水溶性丙泊酚前药与咪唑安定和芬太尼的催眠协同作用 被引量:1
4
作者 栗靖 吴畏 +3 位作者 李涛 易明亮 张文胜 刘进 《华西药学杂志》 CAS CSCD 北大核心 2011年第2期140-143,共4页
目的研究水溶性丙泊酚前药(HX0507)与咪唑安定和芬太尼联合使用时对大鼠催眠效应的相互作用。方法将120只SD大鼠随机均分为HX0507(H)组、咪唑安定(M)组、芬太尼(F)组、HX0507+咪唑安定(H+M)组、HX0507+芬太尼(H+F)组、HX0507+咪唑安定+... 目的研究水溶性丙泊酚前药(HX0507)与咪唑安定和芬太尼联合使用时对大鼠催眠效应的相互作用。方法将120只SD大鼠随机均分为HX0507(H)组、咪唑安定(M)组、芬太尼(F)组、HX0507+咪唑安定(H+M)组、HX0507+芬太尼(H+F)组、HX0507+咪唑安定+芬太尼(H+M+F)组。通过尾静脉穿刺给药,以翻正反射消失作为终点指标,采用序贯法测定各组大鼠的ED50。用Algebraic法分析HX0507和咪唑安定以及芬太尼的相互作用。结果 H、M组的ED50分别为37.16、25.85mg·kg-1;F组的为28.21μg·kg-1;H+M组中HX0507、咪唑安定的分别为5.67、4.11 mg·kg-1;H+F组中HX0507的为11.87mg·kg-1、芬太尼为9.20μg·kg-1。H+M+F组中,在咪唑安定和芬太尼的剂量分别为1.29 mg·kg-1和1.41μg·kg-1时,HX0507的ED50为6.92 mg·kg-1。结论 HX0507与咪唑安定和/或芬太尼联合应用可产生较强的催眠协同作用,减少HX0507的用量。 展开更多
关键词 hx0507 咪唑安定 芬太尼 静脉注射 药物协同作用
原文传递
注射用磷丙泊酚钠在Ⅰ期临床耐受性试验中对健康受试者QT间期的影响
5
作者 伊晓倩 李蕊 +3 位作者 张文胜 刘进 徐晶 廖天治 《四川大学学报(医学版)》 CAS CSCD 北大核心 2012年第6期868-872,共5页
目的探讨注射用磷丙泊酚钠(HX0507)在Ⅰ期临床耐受性试验中对健康受试者心电图QT间期的影响,了解其临床应用可能存在的风险。方法将80例健康受试者顺序分配到13个剂量组。给药前记录基础心电图,并于给药后24h内33个时点记录心电图。求... 目的探讨注射用磷丙泊酚钠(HX0507)在Ⅰ期临床耐受性试验中对健康受试者心电图QT间期的影响,了解其临床应用可能存在的风险。方法将80例健康受试者顺序分配到13个剂量组。给药前记录基础心电图,并于给药后24h内33个时点记录心电图。求得使用Fridericia公式和Bazett公式校正的QT间期,即QTcF(QTcF=QT/RR0.33)与QTcB(QTcB=QT/RR0.5)。以QTcF与基线值的差值(ΔQTcF)为主要目标变量分析HX0507对健康受试者QT间期的影响。结果注射用磷丙泊酚钠在可能的临床常用剂量(3mg/kg)和更大剂量(8~40mg/kg)组给药后ΔQTcF均值在5.61~32.24ms间,双侧90%可信区间上限在10.30~53.90ms间。32例受试者出现了8种心电图相关的不良反应。结论注射用磷丙泊酚钠在3mg/kg和8~40mg/kg剂量组对健康受试者QT间期有剂量相关性延长的趋势。 展开更多
关键词 注射用磷丙泊酚钠 QT间期 Ⅰ期临床耐受性试验
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部